Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 16, 2017
Which drugs does patent RE44874 protect, and when does it expire?
| Title: | Phenethanolamine derivatives for treatment of respiratory diseases |
| Abstract: | The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases ##STR00001## |
| Inventor(s): | Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB) |
| Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
| Application Number: | 13/719,797 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Use; Process; Device; Delivery; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA. | ||||||||||||||||
Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS | ||||||||||||||||
Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER | ||||||||||||||||
Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-002 | Apr 30, 2015 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER | ||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0122201.7 | Sep 14, 2001 |
| United Kingdom | 0126997.6 | Nov 9, 2001 |
| PCT Information | |||
| PCT Filed | September 11, 2002 | PCT Application Number: | PCT/GB02/04140 |
| PCT Publication Date: | March 27, 2003 | PCT Publication Number: | WO03/024439 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,361,787 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||||||||||||||||
| 7,776,895 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | ► Subscribe | |||||||||||||||||||||||||||
| 7,439,393 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||||||||||||||||
| 7,982,067 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||||||||||||||||
| 8,198,483 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 1425001 | ► Subscribe | CR 2014 00021 | Denmark | ► Subscribe | ||||||||||||||||||||||||
| European Patent Office | 1425001 | ► Subscribe | C01425001/02 | Switzerland | ► Subscribe | ||||||||||||||||||||||||
| European Patent Office | 1425001 | ► Subscribe | CA 2014 00021 | Denmark | ► Subscribe | ||||||||||||||||||||||||
| European Patent Office | 1425001 | ► Subscribe | C300664 | Netherlands | ► Subscribe | ||||||||||||||||||||||||
| European Patent Office | 1425001 | ► Subscribe | PA2014019 | Lithuania | ► Subscribe | ||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,310 others who get our Drug Patent Expiration Alerts:
